talactoferrin alfa has been researched along with Cross Infection in 1 studies
talactoferrin alfa: recombinant human lactoferrin, an oral drug for treatment of refractory solid tumors; in Phase I trial 5/2006
Cross Infection: Any infection which a patient contracts in a health-care institution.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sherman, MP | 1 |
| Adamkin, DH | 1 |
| Niklas, V | 1 |
| Radmacher, P | 1 |
| Sherman, J | 1 |
| Wertheimer, F | 1 |
| Petrak, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1/2 Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants[NCT00854633] | Phase 1/Phase 2 | 120 participants (Anticipated) | Interventional | 2009-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for talactoferrin alfa and Cross Infection
| Article | Year |
|---|---|
Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants.
Topics: Administration, Oral; Bacteremia; Cross Infection; Double-Blind Method; Enterocolitis, Necrotizing; | 2016 |